Dow Expands Presence in Pharmaceutical Market
Dow is expanding its presence in the pharmaceutical market, uniting several of its existing offerings under the Dowpharma portfolio. Reflecting the industry's need for a single source contract manufacturer of both pharma and biopharma technologies, Dowpharma now encompasses a significantly broader range of services enabling more rapid and seamless development and production.
The new Dowpharma portfolio includes a full spectrum of development and manufacturing services for the production of synthetic pharmaceutical intermediates and active ingredients. The portfolio includes an extensive chiral technology offering, nucleic acid medicines manufacturing, biopharmaceutical contract development and production by microbial and plant-based systems, radiopharmaceutical development, and drug delivery including solubilization services.
"Customers have told us they need a CMO with a full range of skills as well as demonstrated performance in project execution, regulatory compliance, and technical expertise to help their drugs progress to commercialization, and we can provide this," states Nick Hyde, business director, Dowpharma.
The new strategic mix reflects Dow's commitment to provide a wide array of capabilities and expertise, delivered seamlessly, and tailored to each customer's needs. "By listening carefully, and through meaningful discussion, we will deliver solutions to optimize the products and processes of both large and small pharmaceutical companies as well as emerging companies that have everything riding on a single molecule," says Hyde.
Other news from the department business & finance
These products might interest you
Milli-Q® Services / MyMilli-Q™ by Merck Life Science
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online
Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service
